| Dr R Phillip Dellinger, MD | |
|
1 Cooper Plz, Dorrance 372a, Camden, NJ 08103-1461 | |
| (856) 342-3084 | |
| (856) 968-8306 |
| Full Name | Dr R Phillip Dellinger |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Critical Care Medicine |
| Location | 1 Cooper Plz, Camden, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336246453 | NPI | - | NPPES |
| 1438732 | Other | NJ | UNITED HEALTH PLAN |
| 1159672 | Other | NJ | HORIZON-NJ HEALTH |
| 35752 | Other | NJ | UNIVERSITY HEALTH PLAN |
| 3K6057 | Other | NJ | HEALTHNET, INC |
| P2631132 | Other | NJ | OXFORD HEALTH PLAN |
| 10654693 | Other | NJ | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | MA73770 (New Jersey) | Primary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD421994 (Pennsylvania) | Secondary |
| Entity Name | Cmc Department Of Medicine Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679605554 PECOS PAC ID: 2163335878 Enrollment ID: O20050203000280 |
News Archive
Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.
The fear of public speaking is the most common among individuals with SAD, as well as in the general population. The results of the study are published in the March issue of the Archives of General Psychiatry.
Oh, to be a fly on the wall at this meeting: Health and Human Services Secretary Tommy Thompson, in his tour yesterday (June 8, 2004) of National Institutes of Health (NIH) headquarters, heard about the NIH's prime example of taxpayer-funded translational research - development of a new kind of hearing aid that was inspired by basic biological studies of a tiny fly's ear.
Daiichi Sankyo, Inc. and its parent company, Daiichi Sankyo Co., Ltd, have reached an agreement with Apotex Inc. and Apotex Corp. to settle their patent litigation involving Apotex's challenge to Daiichi Sankyo's U.S. Patent Number 5,340,821 covering Evoxac® (cevimeline HCl).
Despite progress in raising the vaccination rates in the world's poorest countries, some countries, including the Democratic Republic of Congo, Ethiopia, India, Indonesia and Nigeria continue to have vaccination rates "below 50% in certain regions, compared with the 80% or more needed to achieve a low risk of the disease spreading," Douglas Holt, Oxford University professor of marketing, and Jacob McKnight, also of Oxford University, write in a Livemint.com analysis piece.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr R Phillip Dellinger, MD 1 Cooper Plz, Keleman 404, Camden, NJ 08103-1461 Ph: (856) 342-2057 | Dr R Phillip Dellinger, MD 1 Cooper Plz, Dorrance 372a, Camden, NJ 08103-1461 Ph: (856) 342-3084 |
News Archive
Zafgen, a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced positive topline results from its Phase 1b study of ZGN-433, a methionine aminopeptidase 2 inhibitor, for the treatment of severe obesity.
The fear of public speaking is the most common among individuals with SAD, as well as in the general population. The results of the study are published in the March issue of the Archives of General Psychiatry.
Oh, to be a fly on the wall at this meeting: Health and Human Services Secretary Tommy Thompson, in his tour yesterday (June 8, 2004) of National Institutes of Health (NIH) headquarters, heard about the NIH's prime example of taxpayer-funded translational research - development of a new kind of hearing aid that was inspired by basic biological studies of a tiny fly's ear.
Daiichi Sankyo, Inc. and its parent company, Daiichi Sankyo Co., Ltd, have reached an agreement with Apotex Inc. and Apotex Corp. to settle their patent litigation involving Apotex's challenge to Daiichi Sankyo's U.S. Patent Number 5,340,821 covering Evoxac® (cevimeline HCl).
Despite progress in raising the vaccination rates in the world's poorest countries, some countries, including the Democratic Republic of Congo, Ethiopia, India, Indonesia and Nigeria continue to have vaccination rates "below 50% in certain regions, compared with the 80% or more needed to achieve a low risk of the disease spreading," Douglas Holt, Oxford University professor of marketing, and Jacob McKnight, also of Oxford University, write in a Livemint.com analysis piece.
› Verified 5 days ago
Howard Isadore Kesselheim, D.O. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 2 Cooper Plz, Camden, NJ 08103 Phone: 855-632-2667 | |
Richard Arthur Hellander, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 817 Federal St, Camden, NJ 08103 Phone: 856-583-2400 | |
Sivakoti Nagireddy Guda, M.D Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Haddon Ave Fl 6, Camden, NJ 08103 Phone: 856-757-3500 | |
Steven Mudroch Ii, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 3 Cooper Plz Rm 513, Camden, NJ 08103 Phone: 856-963-3715 Fax: 856-635-1052 | |
Dr. Bradley Foster Bender, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-3150 | |
Dr. Amanda A Valvano, DO Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2000 | |
Niku Thomas, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-2488 |